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Lephalale Municipality, located in the north-west of South Africa 
(SA) in Waterberg District in Limpopo Province,[1] has >40% 
of the national coal reserves.[2] The area has been identified as a 
petrochemical cluster in the Limpopo Employment, Growth and 
Development Plan, with the municipality attaining the status of an 
SA national development node in 2012.[2,3] Lephalale itself comprises 
three major extensions,[1] Lephalale, Onverwacht and Marapong, 
and together these areas constitute 18.8% of the Waterberg District 
population (745  748 in 2016).[4] Since 2009, as a result of the wide 
expansion of coal mining and electricity sectors in the area (e.g. 
Madupi power station),[5] there has been significant economic 
as well as notable population growth,[2,4,6-11] the latter largely due 
to influx of migrant workers, mostly men, seeking employment 
opportunities. [4,12] During the 10-year period up to 2011, a 35.8% 
increase in the Lephalale population had been noted (from 85 272 in 
2001 to 115 767 in 2011).[12] An additional 21.1% population growth 
was documented by 2016 (140 240).[13] This rapid growth is in stark 
contrast to more modest population growth of just 9.8% in Waterberg 
District itself between 2011[10] and 2016,[4,13] and in further contrast 
to the smaller 7.5% population increase noted nationally during the 
same period.[4,10] Lephalale is therefore among the fastest-growing 
economic and industrial centres in the country, with the potential to 
become the future hub of power generation in SA.[3] The area is likely 
to continue to attract an increasing number of migrant workers.
In 2002 in SA, before commencement of the national treatment 
programme in 2004, 6.46 million people were projected to be 
HIV-positive;[14] this estimate had risen to 7.9 million by 2016. [15] 
In 2006, the national HIV prevalence was 13.3%,[16] with only a 
modest decrease in prevalence to 12.7% by 2016, 10 years later. [17] In 
Lephalale Municipality, the area of interest of this study as a rapidly 
growing industrial hub, the prevalence of HIV in 2010 was reported 
to be considerably higher than the national prevalence, at 30.4%. [6,18] 
This figure was almost three times the national HIV prevalence rate 
of 10.5%[19] reported in the same year, and nearly double the estimated 
national 17% prevalence reported for adults aged 15 - 49  years.[19] 
During the same period, HIV prevalence among antenatal women 
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Background. Lephalale Municipality in Limpopo Province, South Africa, has seen significant economic and industrial development owing 
to expansion of the coal mining and power generation sectors. This development has coincided with substantial population growth of 65% 
between 2001 and 2016, attributable to largely (migrant) males living in the area who, overall, outnumbered females by ~121:100. The local 
HIV prevalence is reported to be higher than national rates.
Objectives. Anonymised National Health Laboratory Service CD4+ data were used to document increasing laboratory services workload 
and to establish the burden of advanced (CD4+ count <200 cells/µL) and very advanced (<100 cells/µL) HIV disease among adult patients 
accessing public healthcare in Lephalale between 2006 and 2015.
Methods. A cross-sectional design was used to analyse CD4+ laboratory data. CD4+ outcomes were categorised by volumes of tests, year, 
health facility type, age categories (15 - 19, 20 - 24, 25 - 29, 30 - 34, 35 - 39, 40 - 44, 45 - 49 and >49 years), CD4+ test range (≤50, 51 - 100, 
101 - 200, 201 - 350, 351 - 500 and ≥501 cells/µL) and gender. Median CD4+ counts were calculated.
Results. Extracted Lephalale data comprised 57 490 CD4+ results, with a mean patient age of 34 years. Considerably fewer male than female 
patients had CD4+ counts reported (male/female ratio 0.45:1). CD4+ test volumes showed a five-fold escalation over the study period, 
increasing from 1 458 tests in 2006 to 8 239 in 2015. A considerable burden of advanced and very advanced HIV disease (exceeding 50% 
of all cases) was noted in 2006/2007; by 2015 the proportion had fallen, but was still high at 27%. The overall median CD4+ count in 2006 
(192 cells/µL) confirmed a high burden of advanced disease, with modest improvement to 289 cells/µL by 2015. Between 2006 and 2015, the 
median CD4+ count for females increased from 204 to 405 cells/µL, while that for males increased from 126 to 285 cells/µL. Age analysis 
further revealed that men aged <20 years or >25 years, and specifically those aged 30 - 45 years, had up to 44% more advanced HIV disease.
Conclusions. Lower median CD4+ counts and a dramatic increase in volumes of CD4+ tests performed from 2007 onwards revealed a high 
burden of advanced and very advanced HIV disease in patients accessing care in Lephalale. Viewed together with Statistics South Africa 
census documentation of a disproportionately high number of males compared with females living in the area, these figures suggest that 
improved systems are urgently needed to encourage and accommodate access to HIV care for male (migrant worker) patients living and 
working in emerging industrial centres.
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in Waterberg District, of which Lephalale Municipality is part, 
was slightly lower but still high, reported at 28.1% in 2009,[18] and 
falling very slightly to 27.3% by 2013 and to 25.8% by 2015.[18] In 
the mother province (Limpopo), HIV prevalence among antenatal 
women was also lower than that in the Lephalale area, and reported 
as 21.4%, 20.3% and 21.7% for the years 2009, 2013 and 2015, 
respec tively.[17,18,20]
The National Health Laboratory Service (NHLS) provides all 
clinical pathology laboratory services to hospitals, community clinics 
and primary healthcare (PHC) centres across the country for the 
National Department of Health (NDoH). CD4+ and other laboratory 
reporting, collated through the collection and testing of samples 
in this service, provides an invaluable epidemiological and health 
database resource to enable insights into healthcare services and 
disease burden.[21-27] Previous studies utilising NHLS laboratory 
service data have reported a high burden of both advanced (CD4+ 
count <200 cells/µL) and very advanced (<100 cells/µL) HIV disease 
among South Africans.[21,25,28] Review of laboratory-based data has 
further revealed that Waterberg District, in which the Lephalale 
economic hub is situated, had one of the highest reported burdens of 
advanced HIV disease in SA,[25] with >16% of all patients accessing 
HIV care reported to have very advanced HIV disease (CD4+ count 
<100 cells/µL) during 2010.[25] Evidence of an increasing number of 
patients accessing care in the area and an increasing service burden 
was also seen during NHLS National Priority Programme laboratory 
service review during the same period.[23,27]
Objectives
To investigate the increasing health laboratory service requirements 
and document the burden of advanced and very advanced HIV 
disease among male and female patients who accessed healthcare 
in Lephalale Municipality between 2006 and 2015. A study in this 
specific municipality is of importance, as Lephalale is one of the 
areas in SA where marked industrial and economic development 
is occurring. Consequent marked local population growth is well 
documented as migrant and/or emigrant workers (largely males) 
move into the area to take advantage of employment opportunities. 
Acknowledging that there are many other emerging economic and 
industrial hubs across the country, and that the SA government 
has actively encouraged such growth to reduce the proportion of 
unemployed South Africans,[29] the question was therefore asked: 
how does industrial expansion and consequent population growth in 
regional expanding hubs contribute to the HIV disease burden? This 
question is especially relevant when the population growth can be 
attributed to mostly migrant (and largely male) workers, and because 
it is widely known in SA that HIV-positive men are more likely to 
present late, and with more advanced HIV disease, than their female 
counterparts.[21,30-32]
Methods
A cross-sectional study design was used. Anonymised CD4+ data 
were extracted for patients who accessed care in the health facilities of 
Lephalale Municipality for the calendar years 2006 - 2015, inclusive. 
Data fields extracted from the NHLS Corporate Data Warehouse 
(CDW) included the test episode number, the associated health 
facility location from where the test originated (logged as a location 
code and facility description), the testing laboratory location, and 
anonymised test-linked patient demographics including age and 
gender. The testing laboratory test-‘reviewed’ dates (documenting 
the date on which the CD4+ results were released for clinician 
inspection) were used to determine inclusion in the data extraction. 
Data were prepared and analysed using SAS Enterprise Guide 9.4 
(SAS Institute, USA) and Excel 2016 (Microsoft, USA). CD4+ tests 
were categorised by volume of tests, year, gender, and CD4+ test 
range (≤50, 51 - 100, 101 - 200, 201 - 350, 351 - 500 and >500 cells/
µL). Age categories (15 - 19, 20 - 24, 25 - 29, 30 - 34, 35 - 39, 40 - 44, 
45 - 49 and >49 years) were added, adopted from the 2015 National 
Antenatal Sentinel HIV Prevalence Survey.[18] Mean ages were 
reported with a 95% confidence interval (CI).
CD4+ test volumes were further categorised by level of care 
(i.e. the health facility type from where the sample originated), 
including PHC facility, mobile services and district hospital. Level 
of care refers to the various tiers of clinical service within any given 
patient clinical referral network; clinical services offered in Lephalale 
included consultation at PHC facilities (as the lowest level of care), 
with referral, if required, to a health service with increasing tertiary 
care capability, i.e. PHC facilities and community healthcare centres 
referred patients to district and regional hospitals for various levels 
of specialist care.[33] For each health facility where CD4+ counts 
had been requested, the district health information system (DHIS) 
latitude, longitude and facility type were added. This linked GPS 
and laboratory location information was used to establish where, or 
more precisely at which facility type (PHC, mobile or hospital), the 
patients had presented for care. It is important to note that patients 
were not limited by the referral hierarchy but could present directly 
at hospital level for care. Median CD4+ was calculated and reported 
by year, by healthcare facility type (denoting the level of care) and 
by sex. To document the proportions of male and female patients 
receiving CD4+ counts, the percentage of total tests performed on 
males v. females was reported across each year of study. Among 
males and females receiving CD4+ counts, the burden of advanced 
disease was also assessed by reporting the percentage of severely 
immunocompromised patients whose CD4+ counts fell within 
the ranges of ≤100 cells/µL (very advanced HIV disease) or >100  - 
≤200  cells/µL (advanced HIV disease). Other categories of data, 
including ≥201 - 350, ≥351 - 500 and ≥501 cells/µL, were also 
reported. Data from the national and local Lephalale censuses of 2001 
and 2011, as well as the community surveys of 2007 and 2016, are 
reported with permission from Statistics South Africa (Stats SA). [4,9-11] 
SA national census and community survey data are reported in the 
format of x males to 100 females. For the sake of consistency in this 
study, the data concerning male-to-female proportions reported for 
this work are reported in this Stats SA format.
Ethics clearance for use of anonymised laboratory data was obtained 
from the University of the Witwatersrand (ref. nos M1706108 and 
M160978). Specifically, no patient identifiers were used.
Results
Table 1 outlines the descriptive outcomes over the study period 
between 2006 and 2015, including volume of tests, age, gender and 
CD4+ category. In summary, across the study period, the mean age 
of patients was 34 years, with most samples received for patients in 
the 25 - 29-, 30 - 34- and 35 - 39-year age categories (18% (n=10 226), 
19% (n=11 042) and 16% (n=9 261), respectively). Across all facilities, 
the majority of CD4+ samples were requested for females, which 
remained unchanged over the duration of the study (67%; an overall 
male/female ratio of 45 males per 100 females was noted). The 
median CD4+ count ranged from 192 to 361 cells/µL.
CD4+ test volumes
Fig. 1 reveals the volumes of tests reported by level of care for the 
years 2006 - 2015. CD4+ volumes increased markedly (over 4-fold 
from 1 458 to 6 043) during the first 5 years between 2006 and 2010, 
with an overall ~5-fold increase in the volume of tests reported 
507       June 2020, Vol. 110, No. 6
RESEARCH
(or 465% to 8 239 tests) by 2015 
(Table 1, Fig. 1). At the beginning of 
the study period, in 2006, CD4+ test 
requests came mainly from hospital 
wards/clinics, increasing from 1 269 
in 2006 and reaching 3 354 tests 
by 2011; a 7.6:1 ratio of hospital v. 
PHC CD4+ test requests was noted 
in 2006. This proportion gradually 
decreased over the study period as 
more patients accessed care at PHC 
level, decreasing to 0.5:1 by 2015. In 
PHC facilities, CD4+ test requests 
increased continually year by year, 
with just 166 tests reported in 2006, 
but increasing to 5 431 tests per 
year by 2015 (a 32-fold increase). 
Between 2009 and 2010, the highest 
between-year increase in the 
number of tests requested for the 
PHC facilities was noted (equating 
to ~83% and with an absolute 
increase in number from 1 334 to 
2 439 tests). This was followed by a 
further 46% increase between 2011 
and 2012 (from 2 825 to 4 132), 
thereafter plateauing with smaller 
year-on-year increases noted  of 
between 3% and 15%. Mobile 
service CD4+ requests also grew 
steadily, gradually increasing from 
just 23 tests in 2006 and peaking at 
1  595 by 2011 (a 69-fold increase), 
but with a sharp unexplained 
decrease after 2011, reducing to 
80 tests per annum by 2015.
Median CD4+
Although there was a general 
increase in median CD4+ counts 
across the study period, from the 
lowest recorded median of 187 cells/
µL (2007) and peaking at 361 cells/µL 
in 2015 (Table 1), reported median 
annual CD4+ counts reveal a high 
burden of advanced HIV disease. 
Median CD4+ fluctuated equally for 
patients presenting for care, across 
hospital-based, PHC-based and 
mobile facilities (Fig. 1). In 2006, 
median CD4+ counts from mobile 
and PHC facilities were higher than 
hospital-based cases (indicating less 
advanced disease) at >300 cells/µL; 
in contrast, the median CD4+ count 
of patients presenting for care at 
hospital revealed a higher burden 
of advanced burden of disease, with 
hospital-based patients having a 
median CD4+ count of 177 cells/
µL (Fig. 1). In 2007, while there 
was little year-on-year change in 
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median CD4+ counts at district hospital 
level (172  cells/µL), a sharp increase in 
the number of tests requested reporting an 
increasing burden of advanced HIV disease 
was recorded at both PHC and mobile 
clinics, with median CD4+ counts falling 
to 213 and 216 cells/µL, respectively. This 
trend was confirmed by a continued drop 
in the overall annual median CD4+ count 
to 192 cells/µL in 2006, decreasing still 
further to 187 cells/µL by 2007. During the 
following 2-year period between 2008 and 
2009, a modest rise in the median CD4+ 
count (to 259 and 258 cells/µL for 2008 
and 2009, respectively) was noted. Although 
the median CD4+ count was higher than 
that noted in previous years, suggesting 
some patient enrolment onto antiretroviral 
therapy (ART), a higher burden of advanced 
disease re-emerged between 2010 and 2011; 
median CD4+ counts (irrespective of level 
of care) declined, with district hospital, 
PHC and mobile unit median CD4+ counts 
all dropping (to 236, 274 and 233 cells/
µL, respectively). The biggest decline in 
median CD4+ was noted at PHC level, 
suggesting that patients with more advanced 
disease presented for care at clinic facilities 
during 2010/11. During this same 2010 - 
2012 period, the highest number of CD4+ 
requests from district hospitals was also 
recorded (Fig. 1). The overall burden of 
advanced disease of patients presenting for 
care at PHC level had begun to reduce by 
2013, with a higher median CD4+ count 
recorded at 350 cells/µL.
Analysis of disease burden
Fig. 2 outlines the burden of disease by CD4+ 
count category. Disease burden by gender 
is detailed in Fig. 3. In 2006, the burden of 
advanced and very advanced disease was very 
high, CD4+ samples with a reported count 
of ≤200 cells/µL exceeding 50%. A further 
19% of samples tested had a count >200 but 
<350 cells/µL. Bearing in mind the prevailing 
treatment eligibility CD4+ count thresholds 
of either 200 cells/µL or ≤350  cells/µL, 
>50% of patients and up to 70% of patients 
who presented would have been eligible for 
treatment at that time. Although this HIV 
disease burden had reduced to <30% by 2015, 
the burden of advanced and very advanced 
disease was still high. Although among 
female patients the median CD4+ count 
increased from 211 cells/µL in 2006 to 405 
cells/µL by 2014 (Table 1), the annual median 
CD4+ count for males was considerably 
lower (126 - 285 cells/µL). The burden of 
advanced HIV disease, categorised by age, 
further revealed that men aged <20 years or 
>25 years, and specifically between 30 and 
45 years, had up to 44% more documented 
advanced HIV disease (Fig. 3).
Despite the high burden of advanced HIV 
disease documented in the Lephalale area, 
there was evidence of patient enrolment 
and response to ART, which was reflected 
in the proportion of patients with CD4+ 
counts >350 - 500 cells/µL (Table 1). Whereas 
reported CD4+ samples ≥350 cells/µL com-
prised just 30% of all samples tested in 2006, 
suggesting evidence of recruitment onto 
antiretroviral treatment, increasing to >35% 
in 2008, the proportion of patients with a 
CD4+ count ≥350 cells/µL had reached 51% 
by 2015, presumably as more patients were 
enrolled into care after the 2010/2011 national 
treatment recruitment drives.[34]
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Fig. 1. Details by calendar year (2006 - 2015) of the volumes of CD4+ tests reported for Lephalale 
Municipality, Limpopo Province, South Africa. Data are characterised by level of health service facility, 
including district hospital (dark blue bar), mobile services (light blue bar) and PHC facilities (blue bar). 
Median CD4+ levels are reported (y-axis, right), by year by facility and for females (pink line) and 
males (green line), respectively. Absolute patient numbers with reported CD4+ counts are detailed in the 
accompanying table. (PHC = primary healthcare.)
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Fig. 2. CD4+ count category proportion (%) of CD4+ tests reported for all patients accessing care in 
Lephalale Municipality, Limpopo Province, South Africa, for the years 2006 - 2015. The figure highlights 
those patients who were eligible for treatment according to the prevailing treatment guideline threshold 
of 350 cells/µL (reaching 76% in 2007), and includes patients with very advanced (<100 cells/µL) or 
advanced disease (≥100 - 200 cells/µL). For comparison, categories of ≥201 - 350, ≥351 - 500 and 
>501 cells/µL (suggestive of the proportion of patients linked to care) are also included.
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Discussion
Despite access to antiretroviral treatment 
and increasing enrolment into care, SA has 
a high documented burden of advanced 
and very advanced HIV disease.[21,25,30] 
Other work has also shown that in SA, 
compared with females, fewer males access 
care and more present with an advanced 
disease burden,[21] and that, among these 
immunocompromised patients, at least 4 - 5% 
have documented cryptococcal antigenaemia 
on reflexed screening.[28,35] Across the 
country, some areas have been noted to have 
an even higher burden of advanced HIV 
disease;[25] Waterberg District, for example, 
which includes the area of interest for this 
study, Lephalale Municipality, was one of 
the hotspots previously identified as in need 
of intensified programmatic support. This 
area was noted to have the second-highest 
burden of advanced HIV disease in SA in 
2010,[21,25] with the proportion of severely 
immunosuppressed HIV-positive patients 
presenting for care with a CD4+ count of 
<100 cells/µL exceeding 16%[25] (during 
the same period, the national average was 
~10%,[25,36] with some provinces noted to 
have much lower proportions of severely 
immunocompromised patients, e.g. the 
Western Cape with ~7.7 - 7.9%[25]).
Overall, a clear picture of an increasing 
burden of HIV disease, with insufficient 
resources to meet the service demands of a 
growing local population, emerges from this 
study. Firstly, the data substantiate previous 
estimates[27] of an increasing number 
of patients accessing care; a marked and 
increas ing demand for CD4+ testing (465%) 
was documented over the study period. 
Despite this finding, no increased service 
requirements were evident at either the 
national or the provincial level.[27] Between 
2009 and 2010, in the adjacent province, 
Mpumalanga, the increase in documented 
workload was just 17.4% (data not shown), 
while CD4+ test volumes nationally 
increased by just 17%.[37] Secondly, the 
percentage of patients with a CD4+ count 
<200 cells/µL reached 51% in 2006, and 53% 
in 2007 (Fig.  2). These percentages were 
much higher than those reported nationally 
for the same years[21] and confirmed a 
higher burden of advanced disease among 
patients presenting for care in the Lephalale 
area, especially among males (Fig. 3) and 
specifically in the age categories 15 - 19 and 
30 - 34 years. The burden also coincided 
with an increased number of patients 
attending health facilities in the area during 
the 10-year period (Fig. 1) and the launch 
of the 2010 - 2012 national HIV counselling 
and testing campaign that aimed to test 
20 million people over 20 months.[34]
Numerous annual integrated development 
plans (IDPs) published by the local 
Waterberg and Lephalale provincial and 
municipal government[3,7,8,37] acknowledged 
the marked growth of the local population 
and the increasing burden on local health 
services in the area. These plans indicate 
that Lephalale’s healthcare needs were met 
by just three hospitals (two state and one 
private) and six clinics.[2,3] Currently, the 
state hospital Witpoort serves as a referral 
health facility for Abbotspoort, Seleka 
and Shongoane clinics, while Ellisras 
State Hospital is a referral health facility 
for Marapong, Steenbokpan and Ellisras 
town clinics. Despite descriptions of rapid 
local population growth, very few of these 
documents[2,3,6-8,37] address the upgrading 
and capacitating of both hospital and PHC 
healthcare services that were required to meet 
the growing population needs, especially 
in view of acknowledged HIV prevalence 
estimates exceeding 30% (2013). [3,8,37] Only 
one Lephalale clinic, Marapong, noted in 
the 2013 IDP to have a threefold increase in 
patient load at that time[3] and again in the 
2015/16 IDP,[37] was identified for upgrading; 
the clinic was finally set up in a donated 
old private hospital nearby during 2017, 
after this study concluded.[7,8] Mobile health 
services were provided to fourth- and fifth-
order settlements,[3] >10 km away from any 
health facility within the municipality, but as 
suggested by the data presented here, these 
services were largely terminated from 2012 
onwards (Fig. 1). In 2013, a service level 
agreement between Murray and Roberts 
and the NDoH provided for some privately 
managed, supplementary ART clinic access 
in the vicinity of Ellisras Hospital (personal 
communications, N de Beer, Murray & 
Roberts ART clinic implementations, 2013). 
Unfortunately, determining the number 
of patients enrolled into care during this 
period was beyond the scope of this study. 
Other studies have reported modest uptake 
of ART in a similar context. In KwaZulu-
Natal Province, for example, 39% of patients 
who initially presented were estimated to 
be enrolled into care, and only 40% were 
enrolled into care in a Malawian cohort.[32] 
However, some controlled (study) cohorts 
do suggest higher enrolment.[38]
A significant outcome noted in the 
present study was that women attending care 
outnumbered men by >2:1. These figures 
are in stark contrast to the Stats SA census-
documented higher number of men living 
in the Lephalale area (Fig. 4), especially 
younger men aged 15 - 39 years. In this age 
group, the ratio of men to 100 females in 
census data was noted to be lowest at 37.1 
in 2008, and was recorded at its highest, but 
still reversed, at 49.1 in 2015. The marked 
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discrepancy between numbers of males 
and females attending clinics was also most 
evident among the youngest male patients 
attending care (CD4+ study group, Fig. 4): 
here, a ratio of 10 - 60 males per 100 females 
was noted among male patients aged 15 - 34 
years. The ratio of males to females attending 
care only equalised in patients aged >55.
In the present study, men presenting 
for care were also more ill, with more 
advanced and very advanced HIV disease, 
than their female counterparts (Fig. 3); 
this was especially the case among men 
aged >25  years, and these proportions 
were higher than those reported nationally 
during the same period.[21] This finding 
and the predominantly female patient 
presentation and the more advanced disease 
burden among men have been widely 
reported. [21,30,39,40] The Johannesburg-based 
Themba Lethu Clinical Cohort,[31,39] for 
example, reported predominantly females 
attending both pre-ART and ART care, and 
a higher burden of advanced disease among 
men presenting for care. Other local studies 
also report that men initiate ART with 
more advanced HIV disease (lower CD4+ 
counts)[31,39-42] and have higher mortality and 
morbidity, poorer response to treatment 
and worse outcomes than their female 
counterparts.[31] A study on the prevalence 
of late presentation for HIV care among 
newly diagnosed patients in three high-
burden districts across 35 PHC facilities in 
SA[30] also shows that males, particularly 
older males, presented late and with more 
advanced disease: more males than females 
were classified as ‘extreme late’ presentation 
(45.5% v. 26.7%), and more males presented 
with clinical manifestations of AIDS 
(WHO stage IV) and/or a CD4+ count 
≤200 cells/μL.[30]
The predominance of males living in 
the Lephalale area is especially relevant 
and warrants consideration. Census and 
community survey data[4,10] suggest a largely 
migrant community, with census and other 
data documenting that men predominate 
in Lephalale Municipality (Fig. 4); a male/
female ratio as high as 189:100 among adults 
aged 25 - 29 years was documented in one 
report.[13] In addition, this report confirms 
an influx of males seeking employment: the 
community survey of 2016[4,13] had reported 
a 21.8% increase in the male population 
compared with only 13.5% for females that 
year, with an overall population increase of 
18%. This is relatively low compared with 
the 35% increase in the population reported 
for 2011.[13] The latter community survey[13] 
additionally noted that the population 
growth of the area was substantially higher 
than the provincial growth rate of just 0.84% 
per year for the 5 years preceding 2016.
The disparity between the high local HIV 
prevalence in Lephalale, the low number 
of men attending HIV care and the high 
number of males residing in the area draws 
attention to the underlying reasons why 
men, despite availability of ART, are less 
likely than women to present for testing in 
the first instance,[42] and why they present 
late for care with advanced disease. The 
finding also draws attention to the risks 
and challenges posed when a largely male 
community migrates into such areas to 
seek employment. Apart from the obvious 
reasons, including that the scale-up of 
ART in SA has focused on women and 
children, with specific mention in local 
treatment guidelines[43] as well as high-level 
political support[44] and specifically directed 
programmatic funding,[45] the reasons why 
men do not readily access care are complex 
and dependent on numerous factors.[42,44,46-57] 
Fewer men may test for HIV and initiate 
treatment, with stigma described as a major 
limiting factor; a cross-sectional population-
based survey in Limpopo reported that 
males tested for HIV/AIDS less frequently 
than women, and reported more anticipated 
stigma.[42] Men have also been reported 
to view public health facilities as a place 
for women and antenatal care,[48,51] and in 
consequence lacked knowledge about ART. 
It is therefore not surprising that several 
studies have reported that men would prefer 
to attend single-sex health facilities which 
additionally offer extended hours of health 
services and are in close proximity to their 
homes or public transport hubs.[41,48,51] 
Reluctance of males to attend clinic care 
has further been attributed to ‘being made 
to feel guilt, shame and loss of dignity as a 
result of the discrimination by healthcare 
providers and other community’,[48-54] 
especially in the context of engagement in 
risky sexual behaviour away from home.[55-59] 
One study also reported male experiences 
with female nurses who were rude and/or 
judgemental. [51] Masculine norms embedded 
in society can also play an important role in 
acting as barriers to care, including norms 
that shape men’s sexual behaviour[48] and self-
reliance behaviour,[42,49,50,54] or societal gender 
norms that emphasise women’s vulnerability 
and men’s lack of vulnerability. Fears that 
being HIV-positive would threaten men’s 
traditional roles (as father, provider and 
husband) as well as reduce sexual success 
with women[42] have also been described.
Further complexity is added when HIV-
positive men are migrant workers temporarily 
living in a place of employment, such as 
the context of this study – a fast-growing 
economic hub with rapid population growth 
that has attracted an increased number of 
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men, especially younger men, seeking employment. Migrant working 
men have been described as a vulnerable group[55-57] who are 
marginalised and discriminated against.[57] According to Rai and 
colleagues,[52,55,56] HIV-positive migrant men often attend public 
sector HIV services even later than their HIV-positive counterparts 
who are not migrants, often only after they develop debilitating 
symptoms. Even if they are enrolled into care, although there may 
be some response to treatment, recovery among HIV-positive males 
tends not to be as good as that in their female counterparts,[31] and 
they fail to achieve the CD4+ levels and immune reconstitution 
noted in women. These men frequently experience reduced physical 
strength as a result of their illness,[52] and their situation is made worse 
by discriminatory employment policies and practices, including 
informal or casual employment, and poor organisation of migrant 
workers. Most men in this context also lack financial protection 
against onset of illness. As with general clinic access, access to 
care and poor adherence to HIV therapy are also exacerbated by 
inconvenient clinic opening hours and long waiting times,[47,51,57] 
with lack of systems for transferring health records to other centres. 
All these factors result in further hardship and increasing ill health 
and poverty, the trap that led them to migrate for employment in the 
first place.[56,57] Alcohol consumption may also play a negative role in 
adherence to treatment.[58,59]
Rai et al.[55] described HIV-positive individuals in a circular 
migrant labour system as a sub-epidemic and ‘bridge’ population who 
are at risk of, and transmit, infection: migrant labourers are infected 
by a high-prevalence group in the area where they live and work, and 
transmit disease to individuals back at home who would otherwise 
have little or no risk of infection. The high burden of advanced and 
very advanced HIV disease in the context of a largely migrant (male) 
community noted in the present study supports this view. Identifying 
HIV-positive individuals who live and work in emerging industrial 
hubs[52,55,56] as a separate key population to which care should be 
targeted in local SA HIV treatment programmes may assist in 
encouraging enrolment onto ART and help to reduce new infections 
and the burden of advanced and very advanced HIV disease in 
this group. Additionally, considering amendments to labour laws 
to properly support migrant workers and oblige employers to look 
after the health of their employees could further secure the health 
of this economically active group, save health costs, and save lives 
of these workers and their families. The introduction of men-only 
health services,[41] with flexible hours and run by male health workers, 
situated adjacent to mines and service utilities like Medupi,[5] or run 
in a similar way by employers (like Murray & Roberts and Eskom), 
could address barriers to access and improve enrolment into care.[41] 
Furthermore, interventions that pay attention to men’s health, take 
cognisance of men’s behaviour,[49] challenge masculine norms and 
promote gender equality[47] and stop victim blaming[60] could also 
help to address the barriers that men in these contexts face when 
presenting for HIV testing and care. Such approaches could also 
optimise HIV and sexually transmitted disease prevention efforts, 
not to mention addressing other socioeconomic issues, including 
gender-based violence, that play important roles in presentation 
for HIV screening. Local programmes such as the Sonke Gender 
Justice Network for HIV/AIDS Gender Equality and Human Rights 
‘One Man Can’ campaign,[47] without reifying harmful hegemonic 
aspects of masculinity and norms used in some reported public 
health messaging (e.g. ‘Man Up Monday’[61]), have made progress, 
focusing on transformative gender roles and encouraging men to test 
for HIV and attend care. Urgent and clear financial and sociopolitical 
support for such bold approaches is needed in SA to improve the 
lives of infected/affected men, but equally to end gender inequality[62] 
and improve the lives of the women/partners and vulnerable gender 
minority groups with whom men associate.
Study limitations
This study addressed the burden of advanced HIV in a single 
municipality. Using the approach described, other similar rapidly 
growing economic hubs across SA could be identified and studied 
to inform health policy and assist health authorities in the scale-
up of and access to appropriate health services in such areas. The 
strengthening and adaption of local diagnostic laboratory services 
could additionally assist in delivering optimised healthcare services 
by reducing the time from test request to delivery of laboratory 
reports. This aspect was beyond the scope of this work, but is 
published elsewhere.[63]
The study did not include patients who presented for care at 
private or non-governmental organisation (NGO) health facilities 
(estimated to be ~8.5% by Johnson et al.[63]). Although the Medupi 
workers were included at the launch of the HIV counselling and 
testing campaign initiative in 2011,[65] these men may or may not 
have been represented in this public healthcare data cohort (as many 
workers employed by coal mining and electricity production plants 
may access healthcare services at their workplace).[64,65]
This work also did not address retention in care. A systematic 
literature review assessing retention from the time of ART eligibility 
to initiation in sub-Saharan Africa, reporting retention rates ranging 
from 39% to 84% in SA, is published elsewhere.[32]
Furthermore, although there is an association of HIV prevalence 
with very high local population growth and it is likely that this 
impacted on the burden of patients presenting for care in the clinics, 
this was not directly proven.
Lastly, the integration of databases of population statistics and 
HIV prevalence, with linked health and laboratory data, is vitally 
important for future work to accurately assess the HIV and related 
disease burden and access to healthcare, not only in economic hubs 
but throughout SA.
Conclusions and study highlights
While it is widely known in SA that men are more likely than 
women to present late and with advanced HIV disease, the current 
study has documented an increased burden of advanced and very 
advanced HIV disease among economically active, mostly younger 
and largely migrant and/or emigrant men in the context of a rapidly 
growing industrial hub in SA. In these areas, as evidenced by data 
presented here, existing local health facilities may not necessarily 
match changing population needs or the rate of industrial expansion. 
There are many similar emerging, rapidly developing economic and 
industrial hubs around SA, such as eMalahleni (previously known as 
Witbank) and more recently Saldanha Bay. In these areas, there are 
likely to be similar population demographics as noted in Lephalale, 
with a disproportionately high number of males who are also likely 
to have a relatively high burden of advanced HIV disease. Although 
our findings may not impact on individual patient clinical decision-
making, the outcomes reported will nonetheless provide context 
and a perspective to policymakers at NDoH or government level, 
and to treating clinicians, about the community (mostly men) who 
go to work and live in developing industrial hubs around SA and 
the substantial risks they face, as outlined in the ‘Discussion’ above. 
These findings warrant a call to action. Further studies to investigate 
and identify local barriers to care are urgently needed, with a special 
focus on working men’s health needs, especially in a context where 
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there is a growing community of mobile, migrant workers. Urgent 
and specific attention needs to be paid to adequately scaling up health 
services and making health services more amenable to men in the 
contexts described, further paying attention to masculine norms as 
confounding, contributing factors.
The methodology used to generate this report is worthy of mention. 
Routine health data systems are commonly aggregate in nature in SA, 
e.g. they are often paper based and collated through the DHIS. This 
study would have been difficult and tedious using such aggregate data 
sources alone. National health laboratory data, on the other hand, are 
automatically collected to enable routine pathology testing across the 
country; related patient health data are passively collected as tests 
are ordered and reported across the NHLS, provided that a quality 
national laboratory service is maintained and the collection of data is 
supported with an appropriate laboratory information management 
system and proper management and curation of the data in the NHLS 
CDW. Analysis of data from this resource can facilitate insights into 
geospatial public health access and disease burden epidemiology, 
as well as assist in identifying areas/programmes that require 
prioritised focus,[21,23,27,36] but without the need for labour-intensive 
clinical intervention studies, epidemiological investigation or field 
assessment. The work presented here was enabled by extraction of 
population-level CD4+ laboratory data from the NHLS database 
described, with detailed demographic and CD4+ test data extraction 
to include >95% of the population attending HIV care in Lephalale 
Municipality. It is therefore an excellent example of the inherent 
worth of NHLS data as an invaluable, significant and important 
national public health repository and resource. 
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